Myrbetriq is the brand name for the drug mirabegron [1]. Both refer to the same active pharmaceutical ingredient used to treat overactive bladder (OAB) [1][2].
What is Mirabegron used for?
Mirabegron is prescribed for individuals experiencing symptoms of overactive bladder, such as urinary urgency, increased urinary frequency, and urge incontinence [2]. It works by relaxing the bladder muscle, which increases the bladder's capacity to store urine and reduces the sudden urge to urinate [2].
How does Myrbetriq work?
Myrbetriq functions as a beta-3 adrenergic agonist [2]. By stimulating beta-3 adrenergic receptors in the bladder's detrusor muscle, it promotes muscle relaxation. This relaxation allows the bladder to hold more urine and mitigates the involuntary contractions that lead to OAB symptoms [2].
When does the patent for Myrbetriq expire?
DrugPatentWatch.com tracks patent information for drugs like Myrbetriq [3]. Specific patent expiry dates are subject to various factors, including patent filings, extensions, and potential litigation [3]. Information regarding the patent status and anticipated expiry of Myrbetriq can be found through specialized patent tracking services [3].
What are the alternatives to Myrbetriq for overactive bladder?
Besides mirabegron (Myrbetriq), other treatment options for overactive bladder include anticholinergic medications, behavioral therapies, and other drug classes [4]. Anticholinergics, such as oxybutynin and tolterodine, were traditionally the first-line pharmacological treatment but can have side effects like dry mouth and constipation [4]. Behavioral therapies involve techniques like bladder training and pelvic floor muscle exercises [4].